Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Accumulated Expenses (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Accumulated Expenses data on record, last reported at $44.6 million in Q1 2025.

  • For Q1 2025, Accumulated Expenses changed N/A year-over-year to $44.6 million; the TTM value through Mar 2025 reached $44.6 million, changed N/A, while the annual FY2024 figure was $36.4 million, 39.56% down from the prior year.
  • Accumulated Expenses reached $44.6 million in Q1 2025 per MRVI's latest filing, up from $36.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $60.2 million in Q4 2023 and bottomed at $29.0 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $42.6 million, with a median of $40.7 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: soared 54.37% in 2022, then plummeted 39.56% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $34.6 million in 2021, then skyrocketed by 54.37% to $53.4 million in 2022, then grew by 12.86% to $60.2 million in 2023, then crashed by 39.56% to $36.4 million in 2024, then grew by 22.51% to $44.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $44.6 million in Q1 2025, $36.4 million in Q4 2024, and $40.7 million in Q2 2024.